Core Insights - Lianyungang Tongyuan Cell Gene Engineering Co., Ltd. has been established with a registered capital of 3 million RMB, fully owned by Tongyuan Pathology Diagnosis Center (Jiangsu) Co., Ltd. [1] Company Overview - The legal representative of the company is Pan Jiagan [1] - The company is classified under the scientific research and technical service industry, specifically in engineering and technical research and development [1] - The business address is located at No. 567 Huaguoshan Avenue, Building 5, 6th Floor, China Medicine Port, Lianyungang Economic and Technological Development Zone [1] Business Scope - The company's business scope includes medical beauty services, life beauty services, drug clinical trial services, cosmetics production, leasing of Class III medical equipment, and operation of Class III medical devices [1] - It also involves cell technology research and application, engineering and technical research and experimental development, human stem cell technology development and application, and various technical services [1] - Additional services include internet data services, big data services, and sales of medical devices and cosmetics [1]

Group 1 - Shandong Mingxiang Biotechnology Co., Ltd. has been established with a registered capital of 10 million yuan, focusing on biomass energy technology services and comprehensive utilization of agricultural and forestry waste [1][2] - The company is co-owned by He Feng Food Co., Ltd. (35% share), Yafang New Ge Feng Agricultural Technology Co., Ltd. (35% share), and Pufang He Guangyuan Animal Health Co., Ltd. (30% share) [3] - The business scope includes cell technology research and application, livestock and fishery feed sales, and animal health monitoring [2][3] Group 2 - The company is located in Gaomi City, Shandong Province, and is registered under the High-Mi City Market Supervision Administration [2] - The operational period of the company is set until July 30, 2025, with no fixed expiration date [2] - The company is classified under the scientific research and technical services industry [2]

Core Viewpoint - Sartorius has expanded its cell technology product line by integrating MatTek into its laboratory products and services division, creating synergies with existing drug development solutions, including cell analysis instruments, reagents, and AI models [1][2]. Group 1: Acquisition Details - Sartorius officially completed the acquisition of MatTek, a subsidiary of BICO Group, on July 1, 2025 [2]. - The acquisition aims to enhance Sartorius's capabilities in cell technology and drug development [2]. Group 2: MatTek Overview - MatTek is a leading developer and manufacturer of human cell microtissues and three-dimensional models, focused on accelerating drug development processes [3]. - The advanced cell models developed by MatTek simulate the structure and function of human tissues, providing more accurate, cost-effective, and reproducible results compared to traditional two-dimensional cell cultures, while also reducing the need for animal testing [3]. - MatTek employs over 80 staff and is headquartered in Ashland, Massachusetts, with a production facility in Bratislava, Slovakia [3].